# Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors

> **NCT00049088** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 24 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** docetaxel
- **BIOLOGICAL:** bevacizumab
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00049088
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-08
- **Primary completion:** 2009-02
- **Final completion:** —
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Administratively complete.
- **Last updated:** 2013-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00049088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00049088, "Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00049088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*